After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Xenon Pharmaceuticals Inc is $2.43B. A total of 0.58 million shares were traded on the day, compared to an average of 969.99K shares.
In the most recent transaction, GANNON STEVEN sold 3 shares of XENE for 30.48 per share on Jun 05 ’25. After the transaction, the Director now owns 7,141 company shares. In a previous transaction on Jan 24 ’25, MORTIMER IAN sold 22,468 shares at 40.20 per share. XENE shares that PRESIDENT & CEO owns now total 31,302.
Among the insiders who sold shares, MORTIMER IAN disposed of 16,315 shares on Jan 27 ’25 at a per-share price of $40.50. This resulted in the PRESIDENT & CEO holding 31,302 shares of XENE after the transaction. In another insider transaction, MORTIMER IAN sold 16,217 shares at $40.08 per share on Jan 23 ’25. Company shares held by the PRESIDENT & CEO now total 31,302.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, XENE has a high of $46.00 and a low of $26.74.
As of this writing, XENE has an earnings estimate of -$0.99 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$0.8 per share and a lower estimate of -$1.1.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $9.19, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.89.
